Fosfomycin and Hypernatremia
Can Oral Fosfomycin Cause Hypernatremia?
Oral fosfomycin (fosfomycin trometamol) does NOT cause hypernatremia because it contains no sodium; hypernatremia is exclusively a risk with intravenous fosfomycin disodium, which delivers 14.5 mEq (333 mg) of sodium per gram of fosfomycin. 1
The critical distinction lies in the formulation:
- Oral fosfomycin trometamol (the 3g sachet used for uncomplicated UTIs) contains the trometamol salt, which is sodium-free and poses no hypernatremia risk 2
- Intravenous fosfomycin disodium delivers massive sodium loads—a typical 8g dose three times daily provides approximately 348 mEq (8g sodium) per day, equivalent to the sodium content of nearly 4 liters of normal saline 3, 4
Intravenous Fosfomycin: High-Risk Populations for Hypernatremia
Patients with cardiac insufficiency, renal impairment, or pre-existing hypernatremia should avoid intravenous fosfomycin entirely due to the extreme sodium burden. 1
Specific High-Risk Groups:
- Older adults with reduced thirst perception are at heightened risk because they cannot compensate for the osmotic load through voluntary water intake 5
- Renal impairment (any degree) dramatically prolongs fosfomycin elimination—half-life extends from 2 hours in normal kidneys to 7–24 hours in elderly patients with creatinine clearance ~40 mL/min 2, 6
- Patients on hemodialysis or hemofiltration require dose adjustment; during a 4-hour hemofiltration session, only 65% of a dose is removed, leaving substantial residual drug and sodium 7
- Cardiac or hepatic insufficiency patients cannot tolerate the volume and sodium load 1
Incidence and Severity of IV Fosfomycin-Induced Hypernatremia
In a retrospective hospital study, 18% (11 of 62 patients) treated with IV fosfomycin developed hypernatremia; 64% of these cases during one year were directly caused by incorrect drug reconstitution (using insufficient water). 3
Key Findings:
- Among 25 European pharmacovigilance reports of IV fosfomycin-induced hypernatremia, 68% were classified as serious adverse events 3
- Hypernatremia was the most common adverse reaction in a Korean study of CRE infections treated with high-dose IV fosfomycin (16–24g daily), occurring in 3 of 12 patients (25%) 4
- Even after implementing training campaigns on correct drug preparation, new hypernatremia cases continued to occur, indicating the risk persists beyond preparation errors 3
Management of IV Fosfomycin-Induced Hypernatremia
Immediate Assessment:
- Check serum sodium, renal function (creatinine, BUN), and volume status immediately when hypernatremia is suspected 5
- Assess for neurological symptoms (confusion, altered mental status, seizures) that indicate severe hypernatremia requiring urgent correction 5
- Determine chronicity—if hypernatremia developed over >48 hours, correction must be gradual to prevent cerebral edema 5
Correction Strategy:
For chronic hypernatremia (>48 hours duration), reduce serum sodium by a maximum of 10–15 mmol/L per 24 hours using hypotonic fluids; faster correction risks cerebral edema, seizures, and permanent neurological injury. 5
- Discontinue IV fosfomycin immediately if hypernatremia develops 3
- Administer hypotonic fluids (0.45% NaCl or D5W) to replace free water deficit 5
- Never use isotonic saline (0.9% NaCl) as initial therapy—it will worsen hypernatremia, especially in patients with impaired renal concentrating ability 5
- Monitor serum sodium every 2–4 hours initially during active correction, then every 6–12 hours 5
Specific Correction Rates:
- Standard patients: maximum 10–15 mmol/L per 24 hours 5
- Acute hypernatremia (<48 hours) can be corrected more rapidly, up to 1 mmol/L per hour if severely symptomatic 5
- Patients with renal impairment require more conservative rates and close monitoring for worsening azotemia 5
Prevention Strategies
The most effective prevention is avoiding IV fosfomycin in high-risk patients (cardiac/renal insufficiency, pre-existing hypernatremia) and ensuring meticulous drug preparation with adequate water volume. 1, 3
Practical Measures:
- Verify correct reconstitution: each gram of IV fosfomycin disodium must be diluted in at least 250 mL of compatible solution 3
- Implement mandatory pharmacist verification of all IV fosfomycin preparations before administration 3
- Monitor baseline and daily serum sodium in all patients receiving IV fosfomycin 3, 4
- Ensure adequate free water intake—patients must drink sufficient water to compensate for the osmotic sodium load 5
- Consider alternative antibiotics in patients with creatinine clearance <40 mL/min, heart failure, or baseline sodium >145 mmol/L 1, 2
Special Considerations in Renal Impairment
Fosfomycin elimination is almost entirely renal; in patients with creatinine clearance ~40 mL/min, the half-life extends to 7–24 hours (versus 2 hours in normal kidneys), causing drug and sodium accumulation. 2, 6
- Dose reduction is mandatory in renal impairment, though specific guidelines vary 6, 7
- During hemofiltration, a 30 mg/kg dose at the beginning and end of each 48-hour session is recommended 7
- Urinary fosfomycin concentrations remain therapeutic (>300 mg/L) for at least 48 hours even in elderly patients with impaired renal function, suggesting less frequent dosing may be adequate 2
Common Pitfalls to Avoid
- Do not assume oral fosfomycin carries hypernatremia risk—only the IV formulation contains sodium 1, 2
- Do not use isotonic saline to correct fosfomycin-induced hypernatremia—it will exacerbate the problem 5
- Do not correct chronic hypernatremia faster than 10–15 mmol/L per 24 hours—rapid correction causes cerebral edema 5
- Do not continue IV fosfomycin when hypernatremia develops—drug withdrawal occurred in only 1 of 11 patients in one study, but should be standard practice 3
- Do not rely solely on training to prevent preparation errors—systematic checks and pharmacist verification are essential 3